AU8640501A - Innate immune system-directed vaccines - Google Patents

Innate immune system-directed vaccines

Info

Publication number
AU8640501A
AU8640501A AU8640501A AU8640501A AU8640501A AU 8640501 A AU8640501 A AU 8640501A AU 8640501 A AU8640501 A AU 8640501A AU 8640501 A AU8640501 A AU 8640501A AU 8640501 A AU8640501 A AU 8640501A
Authority
AU
Australia
Prior art keywords
immune system
innate immune
directed vaccines
vaccines
directed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU8640501A
Inventor
Ruslan M Medzhitov Ph D
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/752,832 external-priority patent/US20020061312A1/en
Application filed by Yale University filed Critical Yale University
Publication of AU8640501A publication Critical patent/AU8640501A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6025—Nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU8640501A 2000-07-31 2001-07-31 Innate immune system-directed vaccines Pending AU8640501A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22204200P 2000-07-31 2000-07-31
US25832900P 2000-12-28 2000-12-28
US09/752,832 US20020061312A1 (en) 2000-07-31 2001-01-03 Innate immune system-directed vaccines
US28260401P 2001-04-09 2001-04-09
PCT/US2001/024228 WO2002009748A1 (en) 2000-07-31 2001-07-31 Innate immune system-directed vaccines

Publications (1)

Publication Number Publication Date
AU8640501A true AU8640501A (en) 2002-02-13

Family

ID=27499260

Family Applications (2)

Application Number Title Priority Date Filing Date
AU8640501A Pending AU8640501A (en) 2000-07-31 2001-07-31 Innate immune system-directed vaccines
AU2001286405A Ceased AU2001286405B2 (en) 2000-07-31 2001-07-31 Innate immune system-directed vaccines

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2001286405A Ceased AU2001286405B2 (en) 2000-07-31 2001-07-31 Innate immune system-directed vaccines

Country Status (5)

Country Link
EP (1) EP1322326A4 (en)
CN (1) CN1549726A (en)
AU (2) AU8640501A (en)
CA (1) CA2418036A1 (en)
WO (1) WO2002009748A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
DE69932717T2 (en) 1998-05-22 2007-08-09 Ottawa Health Research Institute, Ottawa METHODS AND PRODUCTS FOR INDUCING MUCOSAL IMMUNITY
US8703146B2 (en) 2001-04-20 2014-04-22 Institute For Systems Biology Toll-like receptor 5 ligands and methods of use
ATE463505T1 (en) 2001-04-20 2010-04-15 Inst Systems Biology TOLL-LIKE RECEPTOR 5 LIGANDS AND METHODS OF USE
DE10217254A1 (en) 2002-04-15 2003-10-23 Proteosys Ag Prevention or treatment of tumors comprises treating eukaryotic cells with an agent that modulates the expression and/or function of proteins synthesized and/or secreted by tumors
AU2003300919A1 (en) 2002-12-11 2004-06-30 Coley Pharmaceutical Gmbh 5' cpg nucleic acids and methods of use
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
US7807171B2 (en) 2003-07-25 2010-10-05 Ac Immune Sa Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
EP2174665B1 (en) * 2003-10-22 2016-11-16 ID Biomedical Corporation of Quebec Compositions and methods for activating innate and allergic immunity
CA2594612A1 (en) 2005-01-19 2006-07-27 Vaxinnate Corporation Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response
TW201402124A (en) * 2005-08-19 2014-01-16 Array Biopharma Inc 8-substituted benzoazepines as toll-like receptor modulators
WO2007103322A2 (en) 2006-03-07 2007-09-13 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
CA2706425A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
JP2011519828A (en) 2008-04-18 2011-07-14 バクシネート コーポレーション Flagellin deletion mutants and methods of use
US9289488B2 (en) 2010-08-12 2016-03-22 Ac Immune Sa Vaccine engineering
CN103189050B (en) 2010-10-26 2017-09-29 Ac免疫有限公司 The construct based on liposome comprising the peptide modified by hydrophobic part
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
CA2840988A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Wt1 peptide cancer vaccine composition for mucosal administration
RU2679889C2 (en) * 2013-04-18 2019-02-14 Армо Байосайенсиз, Инк. Methods of using interleukin-10 for treating diseases and disorders
US10639280B2 (en) * 2015-06-02 2020-05-05 De Staat Der Nederlanden, Vert.Door De Minister Van Vws, Ministerie Van Volksgezonheid, Welzijn En Sport Surface display of antigens on gram-negative outer membrane vesicles
US10675589B2 (en) * 2015-10-14 2020-06-09 Novozymes A/S Cleaning of water filtration membranes
JP2019514939A (en) 2016-04-26 2019-06-06 クー バイオロジックス インコーポレイテッドＱｕ Ｂｉｏｌｏｇｉｃｓ Ｉｎｃ． Therapeutic induction of innate immune response in target tissues
CN115317603A (en) * 2016-07-07 2022-11-11 小利兰·斯坦福大学托管委员会 Antibody adjuvant conjugates
CN112940135A (en) * 2019-12-11 2021-06-11 四川农业大学 Fusion protein, amino acid sequence, coding nucleotide sequence, preparation method and application thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1331355C (en) * 1986-04-21 1994-08-09 Bioenterprises Pty. Ltd Immunopotentation
DE68926919T2 (en) * 1988-09-26 1997-01-30 Biotech Australia Pty Ltd Vaccine against nematodes
ATE195076T1 (en) * 1989-03-09 2000-08-15 American Cyanamid Co METHOD FOR ISOLATION OF HAEMOPNILUS INFLUENZAE PROTEIN-E
CA2067144A1 (en) * 1990-08-08 1992-02-09 Heimo Breiteneder Allergens of alder pollen and applications thereof
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
CA2218385A1 (en) * 1995-04-17 1996-10-24 Pierre Hauser Induction and enhancement of the immune response to polysaccharides with bacterial lipoproteins
US6251405B1 (en) * 1995-06-07 2001-06-26 Connaught Laboratories, Inc. Immunological combination compositions and methods
DE19529302A1 (en) * 1995-08-09 1997-02-13 Siemens Ag Device for compensating harmonic currents of a transmission path consisting of several conductors
EP1061950B1 (en) * 1998-02-06 2005-01-26 Research Development Foundation Live vaccine for human immunodeficiency virus
AU3005499A (en) * 1998-03-16 1999-10-11 Henry M. Jackson Foundation For The Advancement Of Military Medicine Induction and enhancement of the immune response to type-2 cell-independent antigens conjugated to lipid or lipid-containing moieties
FR2776521B1 (en) * 1998-03-27 2000-12-15 Pf Medicament USE OF P40 ACTIVE CONJUGATES BY NASAL

Also Published As

Publication number Publication date
WO2002009748A1 (en) 2002-02-07
AU2001286405B2 (en) 2007-05-10
EP1322326A4 (en) 2005-08-17
CA2418036A1 (en) 2002-02-07
WO2002009748A9 (en) 2003-04-03
EP1322326A1 (en) 2003-07-02
CN1549726A (en) 2004-11-24

Similar Documents

Publication Publication Date Title
AU8640501A (en) Innate immune system-directed vaccines
AU4433702A (en) Vaccines
GB0020953D0 (en) Vaccine
HUP0301043A3 (en) Vaccine
IL155072A0 (en) Vaccine
HUP0202885A3 (en) Vaccines
HUP0402259A3 (en) Vaccines
GB0024200D0 (en) Component vaccine
AU1591402A (en) Vaccine
GB0014288D0 (en) Vaccine
AU2002361682A8 (en) Innate immune system-directed vaccines
GB9901254D0 (en) Vaccines
HUP0300354A3 (en) Hiv immune adjuvant therapy
GB0014845D0 (en) Vaccine
GB0026334D0 (en) Vaccine
GB0025694D0 (en) Vaccine
GB0003082D0 (en) Vaccine
GB0004533D0 (en) Vaccines
GB0027433D0 (en) Vaccine component
GB0014437D0 (en) Immune response stimulation
GB0006693D0 (en) Vaccine
GB0015722D0 (en) Vaccine
GB0015935D0 (en) Vaccine
GB0006281D0 (en) Vaccines
GB0014280D0 (en) Vaccines